Definitive Healthcare Corp. DH
We take great care to ensure that the data presented and summarized in this overview for Definitive Healthcare Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DH
View all-
Advent International Corp Boston, MA62.5MShares$178 Million6.01% of portfolio
-
Irenic Capital Management LP New York, NY7MShares$20 Million3.09% of portfolio
-
Massachusetts Financial Services CO Boston, MA4.96MShares$14.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.7MShares$13.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.42MShares$12.6 Million0.0% of portfolio
-
Spectrum Equity Management, Inc. San Francisco, CA2.51MShares$7.15 Million99.77% of portfolio
-
Palisade Capital Management LLC Fort Lee, NJ2.24MShares$6.37 Million0.29% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.86MShares$5.31 Million0.0% of portfolio
-
State Street Corp Boston, MA1.38MShares$3.94 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.31MShares$3.74 Million0.0% of portfolio
Latest Institutional Activity in DH
Top Purchases
Top Sells
About DH
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Insider Transactions at DH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Benjamin Graboske EVP, Chief Data Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,018,330
+50.0%
|
-
|
|
Mar 01
2025
|
Kevin Coop Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,382,892
+38.92%
|
-
|
|
Feb 14
2025
|
Jason Ronald Krantz |
SELL
Payment of exercise price or tax liability
|
Direct |
7,471
-0.76%
|
$37,355
$5.55 P/Share
|
|
Feb 14
2025
|
Jason Ronald Krantz |
BUY
Grant, award, or other acquisition
|
Direct |
16,479
+1.65%
|
-
|
|
Feb 01
2025
|
William Moschella Chief Product & Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,538
-5.95%
|
$114,152
$4.86 P/Share
|
|
Feb 01
2025
|
Richard Douglas Booth CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
27,080
-3.93%
|
$108,320
$4.86 P/Share
|
|
Feb 01
2025
|
Jason Ronald Krantz |
SELL
Payment of exercise price or tax liability
|
Direct |
56,976
-5.57%
|
$227,904
$4.86 P/Share
|
|
Feb 01
2025
|
Kate Marie Shamsuddin CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
16,342
-3.42%
|
$65,368
$4.86 P/Share
|
|
Jan 21
2025
|
William Moschella Chief Product & Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,711
-1.38%
|
$26,844
$4.41 P/Share
|
|
Jan 21
2025
|
William Moschella Chief Product & Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,142
+11.97%
|
-
|
|
Jan 21
2025
|
Richard Douglas Booth CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,192
-1.46%
|
$40,768
$4.41 P/Share
|
|
Jan 21
2025
|
Richard Douglas Booth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
107,480
+13.33%
|
-
|
|
Jan 21
2025
|
Jason Ronald Krantz |
SELL
Payment of exercise price or tax liability
|
Direct |
22,615
-2.16%
|
$90,460
$4.41 P/Share
|
|
Jan 21
2025
|
Jason Ronald Krantz |
BUY
Grant, award, or other acquisition
|
Direct |
178,582
+14.58%
|
-
|
|
Jan 21
2025
|
Kate Marie Shamsuddin CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,331
-1.1%
|
$21,324
$4.41 P/Share
|
|
Jan 21
2025
|
Kate Marie Shamsuddin CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
56,221
+10.41%
|
-
|
|
Jan 01
2025
|
William Moschella Chief Product & Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,421
-3.09%
|
$53,684
$4.11 P/Share
|
|
Dec 14
2024
|
Jason Ronald Krantz |
SELL
Payment of exercise price or tax liability
|
Direct |
4,093
-0.47%
|
$16,372
$4.49 P/Share
|
|
Dec 14
2024
|
Richard Douglas Booth CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,501
-0.25%
|
$6,004
$4.49 P/Share
|
|
Dec 14
2024
|
Kate Marie Shamsuddin CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,044
-0.24%
|
$4,176
$4.49 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.82M shares |
|---|
| Payment of exercise price or tax liability | 288K shares |
|---|---|
| Open market or private sale | 45K shares |